Patents Assigned to Wyeth
  • Circovirus sequences associated with piglet weight loss disease (PWD)
    Patent number: 7244433
    Abstract: The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection is further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.
    Type: Grant
    Filed: July 8, 2005
    Date of Patent: July 17, 2007
    Assignee: Wyeth
    Inventors: André Jestin, Emmanuel Albina, Pierre Le Cann, Philippe Blanchard, Evelyne Hutet, Claire Arnauld, Catherine Truong, Dominique Mahe, Roland Cariolet, François Madec
  • Truncated aggrecanase molecules
    Publication number: 20070161046
    Abstract: Truncated aggrecanase proteins and nucleotides sequences encoding them as well as processes for producing them are disclosed. Additionally, aggrecanases with amino acid mutations that lead to increased stability and expression levels in comparison with wild-type or native aggrecanases are also disclosed. Aggrecanases of the invention are especially useful for development of compositions for treatment of diseases such as osteoarthritis. Methods for developing inhibitors of the aggrecanase enzymes and antibodies to the enzymes for treatment of conditions characterized by the degradation of aggrecan are also disclosed.
    Type: Application
    Filed: December 15, 2006
    Publication date: July 12, 2007
    Applicant: Wyeth
    Inventors: Katy Georgiadis, Tara Crawford, Kathleen Tomkinson, Lisa Collins-Racie, Christopher Corcoran, Bethany Freeman, Edward LaVallie
  • Interleukin-11 compositions and methods of use
    Publication number: 20070160577
    Abstract: The present invention provides methods for the treatment and/or prevention of thrombocytopenia including thrombocytopenia associated with drug-induced liver damage and thrombocytopenia associated with drug-induced bone marrow destruction. The methods of treatment of the invention include administration of interleukin-11 to a subject suffering from or susceptible to thrombocytopenia and/or receiving or about to receive a treatment involving a conjugate therapeutic agent whose administration results in thrombocytopenia. Also provided are pharmaceutical compositions and kits useful for carrying out such methods of treatment.
    Type: Application
    Filed: December 6, 2006
    Publication date: July 12, 2007
    Applicant: Wyeth
    Inventors: Nitin Damle, John DiJoseph, Paul Schendel
  • Beta immunogenic peptide carrier conjugates and methods of producing same
    Publication number: 20070161088
    Abstract: The present invention is directed to methods of producing conjugates of A? peptide immunogens with protein/polypeptide carrier molecules, which are useful as immunogens, wherein peptide immunogens are conjugated to protein carriers via activated functional groups on amino acid residues of the carrier or of the optionally attached linker molecule, and wherein any unconjugated reactive functional groups on amino acid residues are inactivated via capping, thus retaining the immunological functionality of the carrier molecule, but reducing the propensity for undesirable reactions that could render the conjugate less safe or effective. Furthermore, the invention also relates to such immunogenic products and immunogenic compositions containing such immunogenic products made by such methods.
    Type: Application
    Filed: December 17, 2004
    Publication date: July 12, 2007
    Applicants: ELAN PHARMACEUTICALS, INC., WYETH
    Inventors: Rasappa Arumugham, A. Krishana Prasad
  • Antiviral compositions which inhibit paramyxovirus infection
    Publication number: 20070161550
    Abstract: The invention is directed to an antiviral for administration to a mammalian host (e.g., a human) susceptible to paramyxovirus infection, particularly respiratory syncytial virus (RSV) infection. In certain embodiments, an antiviral molecule of the invention is a polypeptide, a chemokine polypeptide, a chemokine polypeptide fragment, an organic small molecule or a peptide mimetic, wherein the antiviral molecule inhibits or prevents paramyxovirus infection of a mammalian cell.
    Type: Application
    Filed: December 28, 2004
    Publication date: July 12, 2007
    Applicant: Wyeth
    Inventors: Gerald Hancock, Paul Tebbey
  • Substituted 4-(indazol-3-yl)phenols
    Patent number: 7241791
    Abstract: This invention provides compound of formulae I or II having the structure wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined in the specification or a pharmaceutically acceptable salt thereof which are useful for the treatment of the inflammatory component of diseases and are particularly useful in treating atherosclerosis, myocardial infarction, congestive heart failure, inflammatory bowel disease, arthritis, type II diabetes, and autoimmune diseases such as multiple sclerosis and rheumatiod arthritis.
    Type: Grant
    Filed: September 24, 2003
    Date of Patent: July 10, 2007
    Assignee: Wyeth
    Inventors: Robert J. Steffan, Edward M. Matelan, Mark A. Ashwell, William R. Solvibile
  • Peptides as solubilizing excipients for transforming growth factor beta proteins
    Patent number: 7241740
    Abstract: The present invention relates to compositions comprising excipients or solubilizing agents for proteins. The invention relates to the discovery that a peptide derived from the N-terminus extension of the T266 isoform of rhBMP-2 has properties that enhance the solubility of proteins. The invention also relates to methods of resolubilizing a protein that has precipitated, by contacting the protein with a peptide comprised of the 17 amino acid extension of the T266 isoform of rhBMP-2. The invention also relates to methods of increasing the solubility of a protein by contacting the protein with a peptide comprised of the 17 amino acid extension of the T266 isoform of rhBMP-2.
    Type: Grant
    Filed: August 12, 2003
    Date of Patent: July 10, 2007
    Assignee: Wyeth
    Inventors: Pilarin E.L. Nichols, Bernardo Perez-Ramirez
  • Oxepane isomer of 42-O-(2-hydroxy)ethyl-rapamycin
    Patent number: 7241771
    Abstract: The invention provides a purified oxepane isomer of 42-O-(2-hydroxy)ethyl-rapamycin (SDZ-RAD Isomer C), a chemical process for its preparation, as well as pharmaceutical compositions and packs containing SDZ-RAD Isomer C and methods for its use as an immunosuppressive, anti-inflammatory, antifungal, antiproliferative and antitumor agent.
    Type: Grant
    Filed: February 22, 2006
    Date of Patent: July 10, 2007
    Assignee: Wyeth
    Inventor: Tianmin Zhu
  • Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
    Publication number: 20070155834
    Abstract: Hydroxamic acids having the formula are useful in treating disease conditions mediated by TNF-?, such as rheumatoid arthritis, graft rejection, cachexia, inflammation, fever, insulin resistance, septic shock, congestive heart failure, inflammatory disease of the central nervous system, inflammatory bowel disease or HIV infection.
    Type: Application
    Filed: February 21, 2007
    Publication date: July 5, 2007
    Applicant: Wyeth Holdings Corporation
    Inventors: Jeremy Levin, Mila Du
  • Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
    Patent number: 7238696
    Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor
    Type: Grant
    Filed: February 13, 2004
    Date of Patent: July 3, 2007
    Assignee: Wyeth
    Inventors: Ronald Charles Bernotas, Yinfa Yan, Albert Jean Robichaud, Guangcheng Liu
  • Recombinant microorganism expressing meningococcal class 1 outer membrane protein
    Patent number: 7238345
    Abstract: Outer-membrane vesicles, Class 1 outer membrane proteins of Neisseria meningitidis, fragments or oligopeptides containing epitopes of the Class I OMP can be used to immunize against meningococcal disease.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: July 3, 2007
    Assignee: Wyeth Holdings Corporation
    Inventors: Robert C. Seid, Jr., Peter R. Paradiso, Jan T. Poolman, Peter Hoogerhout, Emmanuel J. H. J. Wiertz, Peter van der Ley, John Edward Heckels, Ian Nicholas Clarke
  • Lyophilized compositions of a triazolopyrimidine compound
    Publication number: 20070149552
    Abstract: The present invention relates to lyophilized compositions of a triazolopyrimidine compound, or a hydrate thereof, or a pharmaceutically acceptable salt of Compound I or hydrate thereof; solutions useful in preparing said lyophilized compositions; methods for preparing such compositions; methods of reconstituting the same; kits containing such compositions; and uses of the compositions for the treatment of cancer.
    Type: Application
    Filed: December 15, 2006
    Publication date: June 28, 2007
    Applicant: Wyeth
    Inventors: M. Ku, W. Huang
  • Compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists
    Publication number: 20070149585
    Abstract: 3-Amino chroman and 2-amino tetralin derivatives and compositions containing such compounds are disclosed. Such compounds are useful for modulating activity of a 5-HT1A receptor (agonizing or antagonizing) in a patient. These compounds are further useful for inhibiting binding to a serotonin receptor. Methods of using the 3-amino chroman and 2-amino tetralin compounds and compositions containing such compounds in the treatment of serotonin disorders, such as depression and anxiety, are also disclosed.
    Type: Application
    Filed: June 15, 2006
    Publication date: June 28, 2007
    Applicant: Wyeth
    Inventors: P. Ramamoorthy, Zhongqi Shen, Boyd Harrison
  • Process for preparing beta-lactamase inhibitors
    Publication number: 20070149499
    Abstract: The present invention relates to processes for preparing ?-alkylidene penem derivatives that can be important as broad spectrum ?-lactamase inhibitors and anti-bacterial agents.
    Type: Application
    Filed: August 22, 2006
    Publication date: June 28, 2007
    Applicant: Wyeth
    Inventors: Ronald Michalak, Rocco Galante, David Blum, Julianne Blum, Lisa Routel, Haris Durutlic, Charles Guinosso, John Considine, Kenneth Kremer
  • MODIFIED AND STABILIZED GDF PROPEPTIDES AND USES THEREOF
    Publication number: 20070149455
    Abstract: Modified and stabilized propeptides of Growth Differentiation Factor proteins, such as GDF-8 and Bone Morphogenetic Protein-11, are disclosed. Also disclosed are methods for making and using the modified propeptides to prevent or treat human or animal disorders in which an increase in muscle tissue would be therapeutically beneficial. Such disorders include muscle or neuromuscular disorders (such as amyotrophic lateral sclerosis, muscular dystrophy, muscle atrophy, congestive obstructive pulmonary disease, muscle wasting syndrome, sarcopenia, or cachexia), metabolic diseases or disorders (such as such as type 2 diabetes, noninsulin-dependent diabetes mellitus, hyperglycemia, or obesity), adipose tissue disorders (such as obesity), and bone degenerative diseases (such as osteoporosis).
    Type: Application
    Filed: December 21, 2006
    Publication date: June 28, 2007
    Applicant: Wyeth
    Inventors: Neil Wolfman, Soo-Peang Khor, Kathleen Tomkinson
  • Process for preparation of phenethylamine derivatives
    Publication number: 20070149813
    Abstract: A process for the preparation of a compound of formula I, wherein R1 and R2 are ortho or para substituents, independently selected from the group consisting of hydrogen, hydroxyl, C1-C6 alkyl, C1-C6 alkoxy, C7-C9 aralkoxy, C2-C7 alkanoyloxy, C1-C6 alkylmercapto, halo and trifluoromethyl; R3 is hydrogen or C1-C6 alkyl; R4 is hydrogen, C1-C6 alkyl, formyl or C2-C7 alkanoyl; n is one of the integers 0, 1, 2, 3 or 4; and the dotted line represents optional olefinic unsaturation; comprising hydrogenating a compound of formula III, in the presence of a nickel or cobalt catalyst at a temperature of about 5° C. to 25° C.
    Type: Application
    Filed: February 20, 2007
    Publication date: June 28, 2007
    Applicant: Wyeth
    Inventors: Keun-Sik Kim, Kwang-II Kim, Ki-Byung Chai
  • 6-Hydroxyequilenins as estrogenic agents
    Patent number: 7235539
    Abstract: This invention provides estrogen receptor modulators of formula I, having the structure wherein, R1 is hydrogen, alkyl of 1–6 carbon atoms, benzyl, alkylcarbonyl of 2–7 carbon atoms, or benzoyl; X is R2 is hydrogen, alkyl of 1–6 carbon atoms, benzyl, alkylcarbonyl of 2–7 carbon atoms, or benzoyl; R3 is hydrogen, alkyl of 1–6 carbon atoms, hydroxy, or alkoxy of 1–6 carbon atoms; a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a sulfate ester of the hydroxyl group at the 3- or 17-position when R1 or R2 is hydrogen, or a glucuronide of the hydroxyl group at the 3- or 17-position when R1 or R2 is hydrogen.
    Type: Grant
    Filed: January 21, 2003
    Date of Patent: June 26, 2007
    Assignee: Wyeth
    Inventors: Heather A. Harris, James C. Keith, Jr., Leo M. Albert, Galina Vid, Sreenivasulu Megati, Christopher P. Miller
  • Piperidinyl indole and tetrohydropyridinyl indole derivatives and method of their use
    Patent number: 7235569
    Abstract: 3-Piperidin-4-yl-1H-indole and 3-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-indole derivatives are disclosed. Methods of using the derivatives and compositions containing the derivatives in the prevention and/or treatment of serotonin disorders, such as depression and anxiety, are also disclosed. Additionally, processes for the preparation of 3-piperidin-4-yl-1H-indole and 3-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-indole derivatives are disclosed.
    Type: Grant
    Filed: April 30, 2004
    Date of Patent: June 26, 2007
    Assignee: Wyeth
    Inventors: Aranapakam Mudumbai Venkatesan, Osvaldo Dos Santos, Yansong Gu
  • Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders
    Publication number: 20070142423
    Abstract: The present invention provides compounds of the following structure, wherein R1, R2, R4, R4?, R6, R7, and R15 are defined above: These compounds are useful in treating neurological disorders or complications due to stroke or head injury; benign or malignant neoplastic disease, carcinomas and adenocarcinomas; proliferative disorders; and inflammatory disorders. The compounds are therefore useful as neuroprotective and neuroregenerative, anti-proliferative, and anti-inflammatory agents.
    Type: Application
    Filed: January 26, 2007
    Publication date: June 21, 2007
    Applicant: Wyeth
    Inventors: Edmund Graziani, Kevin Pong, Jerauld Skotnicki
  • Control of CCI-779 dosage form stability through control of drug substance impurities
    Publication number: 20070142422
    Abstract: A method of preparing a rapamycin composition having increased potency is provided. The method involves selecting a rapamycin compound having less than 1.5% oxidative and hydrolytic rapamycin impurities and formulating the selected rapamycin with an antioxidant and optional excipients.
    Type: Application
    Filed: December 19, 2006
    Publication date: June 21, 2007
    Applicant: Wyeth
    Inventors: Joseph Rubino, Pooja Gandhi, Lynn Phelan